Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

46 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB. Sandborn WJ, et al. Among authors: pollack pf. Curr Med Res Opin. 2013 May;29(5):483-93. doi: 10.1185/03007995.2013.779575. Epub 2013 Mar 14. Curr Med Res Opin. 2013. PMID: 23438483 Clinical Trial.
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Schreiber S, et al. Among authors: pollack pf. J Crohns Colitis. 2013 Apr;7(3):213-21. doi: 10.1016/j.crohns.2012.05.015. Epub 2012 Jun 16. J Crohns Colitis. 2013. PMID: 22704916 Clinical Trial.
46 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page